Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBC´s 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress

WESTBOROUGH, Mass., May. 07 /PRNewswire/ --

WESTBOROUGH, Mass., May 7 /PRNewswire/ -- IBC Life Sciences announced the keynote line up for the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress, to take place August 4-7, 2008 in Boston, MA. The keynote presentations will include speakers David M. Mott from MedImmune Inc. and Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company. Keynote panel discussions this year will be led by Federico Goodsaid, Ph.D from the FDA, and Mark Ratner from FDC Windhover.

The two individual keynote speakers will discuss the scientific and business strategies that are necessary to move to clinical POC quickly. Keynote panel discussions will approach the more "controversial" topics such as the FDA position on biomarkers and the impact of the 2008 elections on the future of the pharmaceutical/healthcare industry. Presentations include:

4:20 PM, Tuesday, August 5:

Keynote speaker David M. Mott, Chief Executive Officer and President, MedImmune, Inc. will present "Risk-Taking & Innovation in Biotechnology: The MedImmune Success Story."

5:00 PM, Tuesday, August 5:

Keynote panel discussion "Biomarker Qualification in Drug Development: A Regulatory/Industry Discussion" will be led by Federico Goodsaid, Ph.D., Associate Director for Operations in Genomics, Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.

11:20 AM, Wednesday, August 6:

Keynote speaker Elliott Sigal, M.D., Ph.D. Executive Vice President, Chief Scientific Officer and President, Research & Development, Bristol-Myers Squibb Company will discuss "BioPharma of the Future: Blending the Best to Create the Next."

12:00 PM, Wednesday, August 6:

Keynote panel discussion "Leading in a Sea of Change - The Influence of Politics, Change and Innovation on the Future of Pharma/Biotech" will be moderated by Mark Ratner, Contributing Editor, FDC-Windhover.

"Industry experts David Mott and Elliot Sigal being on the program this year will truly bring novel ideas forward," said Michael P. Keenan, Project Manager and Producer, IBC Life Sciences. "In addition, for the first time ever at this event, a tactical FDA Associate Director will discuss the FDA position on biomarkers. And finally, the topic that everyone is thinking about, but never likes to discuss out loud: 'What will the Business and R&D Model of Future 'Big Pharma" Look Like?'' will be among one of the topics addressed in one of our Keynote Panel Discussions."

Complete details on this event can be found at www.drugdisc.com or to receive a press pass or arrange an interview with a speaker, email Keri Dostie at kdostie@ibcusa.com.

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com .

Contact: Keri Dostie IBC Life Sciences 508 - 614 - 1404 kdostie@ibcusa.com